across the UK; we also assessed whether the in vitro activity of tigecycline was further reduced against those isolates with the permeability and efflux changes that, acting in concert with an ESBL or AmpC enzyme, can confer carbapenem resistance.
Eight MIC distributions of tigecycline for referred carbapenemsusceptible and -resistant isolates are shown in Table 1 , together with EUCAST data for susceptible wild-type populations (http:// www.srga.org/eucastwt/WT_EUCAST.htm) and data from the BSAC Bacteraemia Surveillance for 2002 -2004 (http://www. bsacsurv.org.uk). Among Klebsiella spp., the modal MIC was 0.5 mg/L for referred carbapenem-resistant isolates and for the BSAC and EUCAST datasets, but was raised to 1 mg/L for referred carbapenem-susceptible isolates; the reason for this requires further investigation. The modal MIC for all groups of Enterobacter spp. was 0.5 mg/L (Table 1) .
Among referred carbapenem-susceptible Enterobacter spp. isolates, 205 (78%) were susceptible to tigecycline, 35 (13%) were fully resistant, and 24 (9%) had intermediate susceptibility.
No differential was seen between the tigecycline susceptibility of these carbapenem-susceptible isolates and isolates in the BSAC dataset (P ¼ 0.37). However, referred carbapenemresistant Enterobacter spp. isolates were less often susceptible to tigecycline (32/65, 49%; P , 0.0001); with 20 (31%) fully resistant, and 13 (20%) intermediate. In contrast, there was no significant difference in the proportions of tigecycline-susceptible Klebsiella spp. isolates among referred carbapenem-susceptible (303/451; 67%) and carbapenem-resistant isolates (54/89; 60%) (P ¼ 0.27). However, tigecycline non-susceptibility (MICs 2 mg/L) was more frequent in both groups when compared with BSAC bacteraemia isolates (P , 0.0001).
Among new agents, tigecycline is unique in having good activity against Gram-negative bacteria in general. However, these data support the observation that many cephalosporinresistant (i.e. mostly ESBL-producing) Klebsiella spp. isolates require slightly raised tigecycline MICs, 2,3 but refute the hypothesis that further rises occur in this genus contingent on the uptake and efflux changes associated with carbapenem resistance. In contrast, carbapenem-resistant Enterobacter spp. isolates were more likely to show reduced tigecycline susceptibility than carbapenem-susceptible isolates, even when the latter were resistant to cephalosporins. These differences between Enterobacter spp. and Klebsiella spp. remain to be explained. Non-carbapenemase-mediated carbapenem resistance in Klebsiella spp. is associated with porin loss along with ESBLs; the mechanisms in Enterobacter spp. are less clear although AmpC enzyme activity has a role. 1 Porin loss may arise via mutations in porin genes or via changes at global regulatory loci, with the latter also able to affect efflux pumps. Acquired resistance to tigecycline in the Enterobacteriaceae can also involve efflux through up-regulation of intrinsic pumps 4 or mutations in acquired pumps, 5, 6 and has also been associated with changes at a regulatory locus. 7 There is therefore potential for such mechanisms to confer reduced susceptibility to both carbapenems and tigecycline. The mechanisms of reduced tigecycline susceptibility and resistance in cephalosporin-resistant Klebsiella spp. and in carbapenem-resistant Enterobacter spp. are now under investigation.
